Sequences in the Cytoplasmic Tail of the Gibbon Ape Leukemia Virus Envelope Protein That Prevent Its Incorporation into Lentivirus Vectors
- 1 May 2001
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 75 (9), 4129-4138
- https://doi.org/10.1128/jvi.75.9.4129-4138.2001
Abstract
Pseudotyping retrovirus and lentivirus vectors with different viral fusion proteins is a useful strategy to alter the host range of the vectors. Although lentivirus vectors are efficiently pseudotyped by Env proteins from several different subtypes of murine leukemia virus (MuLV), the related protein from gibbon ape leukemia virus (GaLV) does not form functional pseudotypes. We have determined that this arises because of an inability of GaLV Env to be incorporated into lentivirus vector particles. By exploiting the homology between the GaLV and MuLV Env proteins, we have mapped the determinants of incompatibility in the GaLV Env. Three modifications that allowed GaLV Env to pseudotype human immunodeficiency virus type 1 particles were identified: removal of the R peptide (C-terminal half of the cytoplasmic domain), replacement of the whole cytoplasmic tail with the corresponding MuLV region, and mutation of two residues upstream of the R peptide cleavage site. In addition, we have previously proposed that removal of the R peptide from MuLV Env proteins enhances their fusogenicity by transmitting a conformational change to the ectodomain of the protein (Y. Zhao et al., J. Virol. 72:5392–5398, 1998). Our analysis of chimeric MuLV/GaLV Env proteins provides further evidence in support of this model and suggests that proper Env function involves both interactions within the cytoplasmic tail and more long-range interactions between the cytoplasmic tail, the membrane-spanning region, and the ectodomain of the protein.Keywords
This publication has 124 references indexed in Scilit:
- A Hyperfusogenic Gibbon Ape Leukemia Envelope Glycoprotein: Targeting of a Cytotoxic Gene by Ligand DisplayHuman Gene Therapy, 2000
- Stable gene transfer to the nervous system using a non-primate lentiviral vectorGene Therapy, 1999
- Pseudotyping of Moloney leukemia virus-based retroviral vectors with simian immunodeficiency virus envelope leads to targeted infection of human CD4+ lymphoid cellsGene Therapy, 1998
- Improved Gene Transfer into Human Lymphocytes Using Retroviruses with the Gibbon Ape Leukemia Virus EnvelopeHuman Gene Therapy, 1996
- Comparison of Efficiency of Infection of Human Gene Therapy Target CellsviaFour Different Retroviral ReceptorsHuman Gene Therapy, 1996
- In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral VectorScience, 1996
- Inducible, High-Level Production of Infectious Murine Leukemia Retroviral Vector Particles Pseudotyped with Vesicular Stomatitis Virus G Envelope ProteinHuman Gene Therapy, 1995
- Expanded HIV-1 Cellular Tropism by Phenotypic Mixing with Murine Endogenous RetrovirusesScience, 1990
- Site-directed mutagenesis by overlap extension using the polymerase chain reactionGene, 1989
- Characterization of a highly oncogenic murine leukemia virus from wild miceInternational Journal of Cancer, 1982